“So there's really no change to our expectations of a $150 million adverse impact from volume-based procurement in 2025.”

In context

“, you know, new products and kind of other things is the final third. So a third, a third, a third between China, genomics, new products, other. That's sort of what we're assuming and it baked into the model from StepUp. From one half to two half of roughly $150 million. Tycho Peterson: Okay. That's helpful. And then one quick follow-up sounds like you're not flagging any incremental headwinds on volume-based procurement. You know, obviously, one of your periods did last week. Maybe just give it get us comfortable you know, that's not a lingering issue that could get worse. Rainer Blair: So in China, volume-based procurement and the reimbursement changes, was essentially what we thought in Q2. And for the first half of the year. In fact, volume was consistent with Q1 and our expectations. So there's really no change to our expectations of a $150 million adverse impact from volume-based procurement in 2025. Tycho Peterson: Now under the hood there, there's been some recent policy changes. Rainer Blair: Which largely did not affect us. Because they're really geared to different aspects of the testing menu which we actually don't have. So it's possible that different companies experience different things here. But for us, we saw the quarter develop as expected. Volumes were consistent with Q1. And we don't have a different perspective on $150 million here for the year. On volume-based procurement. Tycho Peterson: Okay. That's helpful. Thank you. Rainer Blair: Thanks, Tycho. Margaux: Next, we'll go to Vijay Kumar with Evercore. Please go ahead. Rainer Blair: Good morning, Vijay. Vijay Kumar: Good morning, and thank you for taking my question. Congrats to both Regina and Maguire. Maybe one on bi”